Unknown

Dataset Information

0

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.


ABSTRACT: Programmed cell death-1 (PD-1) and/or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor (ICI) treatments are associated with adverse events (AEs), which may be dependent on ICI dose. Applying a model-based meta-analysis to evaluate safety data from published clinical trials from 2005 to 2018, we analyzed the dose/exposure dependence of ICI treatment-related AE (trAE) and immune-mediated AE (imAE) rates. Unlike with PD-1 inhibitor monotherapy, CTLA-4 inhibitor monotherapy exhibited a dose/exposure dependence on most AE types evaluated. Furthermore, combination therapy with PD-1 inhibitor significantly strengthened the dependence of trAE and imAE rates on CTLA-4 inhibitor dose/exposure.

SUBMITTER: Shulgin B 

PROVIDER: S-EPMC7466858 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6938753 | biostudies-literature
| S-EPMC8235766 | biostudies-literature
| S-EPMC7511303 | biostudies-literature
| S-EPMC7163782 | biostudies-literature
| S-EPMC7905347 | biostudies-literature
| S-EPMC8352266 | biostudies-literature
| S-EPMC8071627 | biostudies-literature
| S-EPMC7183506 | biostudies-literature
| S-EPMC7049490 | biostudies-literature
| S-EPMC5296331 | biostudies-literature